|
 | Up a level |
Sokhela, Simiso, Venter, Willem D.F., Bosch, Bronwyn, Woods, Joana, McCann, Kaitlyn, Akpomiemie, Godspower, Chandiwana, Nomathemba, Mashabane, Nkuli, Tembo, Angela, Simmons, Bryony, Lalla-Edward, Samanta, Siedner, Mark J., Sinxadi, Phumla, Hermans, Lucas, Fairlie, Lee, Vos, Alinda, Abrams, Elaine, Manne-Goehler, Jennifer M., Moorhouse, Michelle, Clayden, Polly, Norris, Shane, Qavi, Ambar, Chersich, Matthew, Masenya, Masebole, Arulappan, Natasha and Hill, Andrew (2024) Final 192-week efficacy and safety results of the ADVANCE trial, comparing 3 first-line antiretroviral regimens. Open Forum Infectious Diseases, 11 (3). ISSN 2328-8957
Tovar Sanchez, Tamara, Mpoudi-Etame, Mireille, Kouanfack, Charles, Delaporte, Eric, Calmy, Alexandra, Venter, Francois, Sokhela, Simiso, Bosch, Bronwyn, Akpomiemie, Godspower, Tembo, Angela, Pepperrell, Toby, Simmons, Bryony, Casas, Carmen Perez, McCann, Kaitlyn, Mirchandani, Manya and Hill, Andrew (2023) Risks of metabolic syndrome in the ADVANCE and NAMSAL trials. Frontiers in Reproductive Health, 5. ISSN 2673-3153
Sokhela, Simiso, Bosch, Bronwyn, Hill, Andrew, Simmons, Bryony, Woods, Joana, Johnstone, Hilary, Akpomiemie, Godspower, Ellis, Leah, Owen, Andrew, Casas, Carmen Perez and Venter, Willem Daniel Francois (2022) Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. The Journal of Antimicrobial Chemotherapy, 77 (10). 2706 - 2712. ISSN 1460-2091
